오름테라퓨틱 Stock: price and insider trades · South Korea
1 insider bought €110k of shares over the last 90 days, the latest by 이승주, filed 29 Oct 2026.
오름테라퓨틱: what insiders have been doing
Every trade that managers of 오름테라퓨틱 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Between 2 November 2025 and 2 November 2026, 5 insiders published 14 filings.
Purchases and sales both appear in the filings: 8 purchases (4 insiders) and 6 sales (3 insiders, €2.8M). No amount is published for 13 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 2 board members and 1 major shareholder. At €2.8M, the sale published on 31 March 2026 by Peter Unnam Park is the largest of the period (0.31% of market cap).
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 14 filings here. Over the whole record (from 2025), the tally stands at 10 purchases and 12 sales.
The latest purchase is recent: it was published 12 days ago, on 29 October 2026. The median gap between a trade and its publication by DART (FSS) is 7 days. Until a filing is published, the market cannot know about the trade.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -82.3%Entry ₩86,500 · Close 30 Oct 2026 ₩15,320
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 10,000 sharesShareKRXDART:20261029000440Canonical exit: 27 Jan 2027 (T+90)
- Other0DART
- 650 sharesKRXDART:20260609000382Canonical exit: 7 Sept 2026 (T+90)
- 100,000 sharesShareKRXDART:20260609000452Canonical exit: 7 Sept 2026 (T+90)
- 3,300 sharesShareKRXDART:20260609000436Canonical exit: 7 Sept 2026 (T+90)
- 39,000 shares@ ₩124,730.15380.31% mcap100.0% of flowShareKRXDART:20260331004314
- 7,134 sharesKRXDART:20260331004705Canonical exit: 25 Jun 2026 (T+90)
- 5,124,754 sharesKRXDART:20260219002636
- 122,517 sharesKRXDART:20260128000255Canonical exit: 17 Apr 2026 (T+90)
- 14,424,392 sharesKRXDART:20260123000280Canonical exit: 17 Apr 2026 (T+90)
- 33,351 sharesKRXDART:20260116000277Canonical exit: 14 Apr 2026 (T+90)
- 597,892 sharesKRXDART:20251205000245
- 322,665 sharesShareKRXDART:20251202000354
- 356,393 sharesKRXDART:20251128000509
- 416,906 sharesKRXDART:20251107000101
- 457,687 sharesKRXDART:20251031000119
- 162,387 sharesKRXDART:20250829001023
- 12,724 sharesKRXDART:20250808000306Canonical exit: 30 Oct 2025 (T+90)
- 169,390 sharesKRXDART:20250808000297Canonical exit: 21 Oct 2025 (T+90)
- 270,266 sharesKRXDART:20250604000230
- 479,356 sharesKRXDART:20250604000223
- 105,354 sharesKRXDART:20250310000393
- 395,525 sharesKRXDART:20250310000382
23 of 23 declarations
About 오름테라퓨틱
Orum Therapeutics is a healthcare and pharmaceutical company listed on the XKRX. It focuses on developing innovative treatments for various diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
